Arthneeti

Rossari Biotech Q2 FY27 Share Price & Earnings Call Analysis

₹407.35+0.28% today
Market cap
₹2,256 Cr
P/E
14.77
ROE
10.77%
PEG
1.81
Price to sales
0.84
Debt to equity
0.28
52W high / low
₹650 / ₹379
Sales growth (5Y)
27.57%
EBITDA margin
11.79%
Net profit margin
5.66%
Promoter holding
68.14%
Sales (last year)
₹2,661 Cr

Guidance scorecard · Q2 FY27 call

What Rossari Biotech's management guided
and where it ranks in Chemicals & Petrochemicals

#37of 68 in
Chemicals & Petrochemicals
Revenue10–20%MarginsUp 0–2%CapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ2 FY27 call

10–20%
  • Rossari Biotech expects mid-teen to high-teen percentage revenue growth for the full year, although geopolitical and logistical uncertainties make exact forecasting difficult.
  • H1 revenue grew 20% YoY, driven largely by volume growth rather than price increases.
  • Ethoxylation capacity ramp-up in Dahej is expected to peak by end of FY28, with a target of 3x CAPEX value as peak sales revenue.
  • Export revenues have been rising steadily, aiming for over 30% of total revenue by year-end, supported primarily by HPPC and Textile segments.

2 more points from Rossari Biotech's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Up 0–2%

See what Rossari Biotech said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Most current CAPEX projects (approx. Rs. 150 crore in CWIP) expected to complete by end of the year.
  • Additional CAPEX spend of Rs. 50-75 crore planned in the second half of the year mainly for pharma, aroma chemicals, and hydrogenation initiatives.
  • Post this, CAPEX in India will be significantly lower.
  • Future major CAPEX planned for a greenfield plant in Saudi Arabia (KSA), currently only land leased; project plan finalization pending.
  • KSA investment will involve equity and debt; details on CAPEX size, returns, and products to be shared once finalized.

2 more points from Rossari Biotech's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

See what Rossari Biotech said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

Ask what Rossari Biotech said on the order book →

Full Q2 FY27 analysis
Full Chemicals & Petrochemicals ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Rossari Biotech rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Chemicals & Petrochemicals companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 0–2%₹234 Cr3.0
240%+Flat₹3,888 Cr48.5
340%+Flat₹3,514 Cr4.3
440%+Flat₹180 Cr11.9
540%+Flat₹138 Cr15.1
620–40%Up 2%+₹1.70L Cr85.4

Sign up free to see every company in the sector ranking and track Rossari Biotech.

Pro shows every company guiding 40%+ revenue growth →Full Chemicals & Petrochemicals ranking

Financials of Rossari Biotech

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Rossari Biotech

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +68.34%68.32%68.32%68.27%68.19%68.18%68.18%68.18%68.15%68.15%68.14%68.14%
FIIs +4.14%4.02%3.83%3.74%3.74%3.98%3.48%2.70%2.32%2.18%2.03%1.84%
DIIs +18.06%17.74%16.87%17.34%17.47%17.59%17.84%18.18%18.25%18.21%14.64%14.19%
Public +9.45%9.90%10.98%10.64%10.60%10.24%10.50%10.95%11.25%11.46%15.19%15.84%
No. of Shareholders1,00,42398,8591,00,47597,18895,73592,85291,79191,38789,24986,97287,58086,622

Financials of Rossari Biotech

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +483464473490498513580544586582685697698
Expenses +420400409425432448510476514513608617611
Operating Profit64646465666569687269778187
OPM %13%14%13%13%13%13%12%12%12%12%11%12%12%
Other Income +14111122212041
Interest54344566689119
Depreciation15151615151818181820242630
Profit before tax45484647484248465043644849
Tax %26%28%25%26%27%25%28%27%26%23%28%26%21%
Net Profit +33343435353234343733463539
EPS in Rs5.976.236.186.326.395.736.226.076.665.928.306.347.02

Financials of Rossari Biotech

Profit & Loss

Annual income statement trend

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +5166007091,4831,6561,8312,0802,3962,661
Expenses +4384955861,2991,4331,5811,8152,1102,348
Operating Profit78105124184223250265286314
OPM %15%17%17%12%13%14%13%12%12%
Other Income +149136852425
Interest343132219182936
Depreciation121723486360677999
Profit before tax6388107136144178185203204
Tax %28%26%25%28%26%26%26%26%
Net Profit +46658098107131136149153
EPS in Rs9.4412.8615.4517.7419.4523.6624.6326.9427.58
Dividend Payout %0%4%3%3%3%2%2%2%

Financials of Rossari Biotech

Balance Sheet

Capital structure and asset base

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital41010111111111111
Reserves1192773987949041,0371,1741,3221,397
Borrowings +8670874119218436388
Other Liabilities +118118152442375401482505564
Total Liabilities2504715611,2551,3641,5671,8862,2742,359
Fixed Assets +7494181607585578598784845
CWIP322011647140173156
Investments0180365163846230
Other Assets +1733383796117128801,0631,2541,328
Total Assets2504715611,2551,3641,5671,8862,2742,359

Financials of Rossari Biotech

Cash Flows

Operating, investing and financing cash movement

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +715748291524313765
Cash from Investing Activity +-37-190-37-299-181-103-183-220
Cash from Financing Activity +-29157-25292611665186
Net Cash Flow523-142232-441931
Free Cash Flow27-19-8-7120-83-21-175
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit118%74%64%43%89%39%74%47%

Financials of Rossari Biotech

Ratios

Working capital efficiency and return ratios

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6157747578858385
Inventory Days5957756359809088
Days Payable114951046156627371
Cash Conversion Cycle619467680103101103
Working Capital Days2322606249706949
ROCE %38%29%24%18%18%16%13%

Guidance history

How Rossari Biotech's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →10–20%Up 0–2%Planned——
Q1 FY27 call →10–20%Up 2%+Planned——
Q4 FY26 call →10–20%FlatPlannedNone planned—
Q3 FY26 call →10–20%FlatPlannedPlanned—

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

10out of 100

Momentum score · price trend

10 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−36.6%15%
Last 6 months−15.3%28%
Last 3 months−20.1%19%

The price is 73.4% below its all-time high of ₹1,527.45 (14 Oct 2021). Stocks more than 20% below their peak have their score halved, so 21 became 10.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Rossari Biotech: 0.4 × 15 + 0.4 × 28 + 0.2 × 19 = 21, halved to 10 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Rossari Biotech's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • J.G.Chemicals (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹3,610 million, up 63.9% YoY (₹2,203 million in Q2 FY26) (Page 23) . Key investor presentation takeaways from J.G.Chemicals Ltd

  • Lords Chloro (Q2 FY27)

    115.40 Crore, up 17.34% YoY from Rs. Key investor presentation takeaways from Lords Chloro Alkali Ltd's Q2 FY27 investor presentation — and how it ranks against

  • Camlin Fine (Q2 FY27)

    Q2 FY27 revenue: Rs 4,915 mn, up 9.15% YoY from Rs 4,503 mn in Q2 FY26 (Page 6, 9) . Key investor presentation takeaways from Camlin Fine Sciences Ltd's Q2 FY27

  • Gujarat Fluoroch (Q2 FY27)

    Consolidated Q2FY27 revenue: ₹1,760 crore, up 45% YoY (Q2FY26: ₹1,210 crore). Key investor presentation takeaways from Gujarat Fluorochemicals Ltd's Q2 FY27 inv

Compare:vs Solar Industriesvs Pidilite Industriesvs SRF